Top Markets
#1 Celer Network Celer Network +41.22%
#2 Gravity Gravity +22.02%
#3 Galxe Galxe +19.80%
#4 MemeCore MemeCore +12.58%
#5 Ontology Gas Ontology Gas +9.96%
#6 Cartesi Cartesi +8.25%
#7 Zilliqa Zilliqa +7.90%
#8 Synapse Synapse +7.43%
#9 Cortex Cortex +7.33%
#10 UnifAI Network UnifAI Network +7.06%
Coin of the day
Celer Network Celer Network
Settings
Language
ENGLISH
Currency
USD
Theme
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rank in Stocks #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Share Price
$0.1559364
Last synced: 2026-09-18
Market Cap
$195.17K
Change (1 day)
6.60%
Change (1 year)
-30.91%
Country
GB
Trade Fusion Antibodies plc (FAB)

Category

Healthcare
Earnings for Fusion Antibodies plc (FAB)
Earnings in Sep 2025 TTM: $-2.06M
According to Fusion Antibodies plc latest financial reports the company's current earnings are $-2.06M. In 2024 the company made an earning of $-2.89M, an increase over its 2023 earnings that were of $-3.53M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Fusion Antibodies plc from 2013 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -256,061.35%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -94,754.12%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 149,694.82%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 194,783.51%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH